Biotech companies are entering the second quarter earnings period ready to challenge major pharmaceutical firms with new drug launches, according to a Jul. 29 report by BioSpace.
More small biotechs are choosing to independently market their drugs rather than partner or sell, creating a dynamic environment as investors watch for signs of success. BioSpace highlights five companies—Agios Pharmaceuticals, Arrowhead Pharmaceuticals, BridgeBio, Ionis Pharmaceuticals, and Ultragenyx—that have significant catalysts in the coming weeks.
Agios Pharmaceuticals will present its second quarter results on July 30 after discontinuing development of tebapivat for sickle cell disease due to disappointing Phase 2 results. The company now faces increased pressure on its remaining pipeline drug mitapivat, which is approved under different names for pyruvate kinase deficiency and thalassemia. Mitapivat is also under review by the Food and Drug Administration via an accelerated pathway for sickle cell disease, with a decision expected November 1.
Arrowhead Pharmaceuticals reported successful Phase 3 studies of plozasiran in severe hypertriglyceridemia, boosting its stock price ahead of its August 4 earnings call. The company expects further data from obesity programs ARO-INHBE and ARO-ALK7 later this year. Arrowhead recently received approval for plozasiran in familial chylomicronemia syndrome and anticipates sales around $6 million this quarter.
BridgeBio’s ATTR-CM therapy Attruby continues to gain market share against established competitors like Pfizer’s Vyndaqel. The company projects quarterly sales of $215 million and is seeking approvals for three additional rare disease treatments that could represent billion-dollar opportunities if successful.
Ionis Pharmaceuticals leads the market with Tryngolza, now approved for two indications but facing revenue declines as it enters broader markets at lower prices. Analysts estimate quarterly revenue at $209 million—a decline from last year—but expect recovery due to positive clinical data showing reduced risk of acute pancreatitis.
Ultragenyx faces challenges following setbacks in bone disease drugs and gene therapies but looks ahead to key regulatory decisions on pariglasgene brecaparvovec and rebisufligene etisparvovec later this year. Jefferies analysts predict Crysvita sales between $500–$520 million, while Dojolvi could generate up to $110 million.
